Resource Summary Report

Generated by RRID on Jul 29, 2026

p38alpha (N-20)

RRID:AB_632140
Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-728, RRID:AB_632140

Antibody Information

URL: http://antibodyregistry.org/AB_632140

Proper Citation: Santa Cruz Biotechnology Cat# sc-728, RRID:AB_632140

Target Antigen: MAPK14, MAPK11

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued: 2016; validation status unknown check with seller; recommendations: ELISA; Immunocytochemistry; Immunofluorescence; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, Immunohistochemistry(P), ELISA

Antibody Name: p38alpha (N-20)

Description: This polyclonal targets MAPK14, MAPK11

Target Organism: rat, mouse, human

Clone ID: N-20

Antibody ID: AB_632140

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-728

Record Creation Time: 20250819T230327+0000

Record Last Update: 20250820T040909+0000

Ratings and Alerts

No rating or validation information has been found for p38alpha (N-20).

Warning: Discontinued: 2016
Discontinued: 2016; validation status unknown check with seller; recommendations: ELISA; Immunocytochemistry; Immunofluorescence; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, Immunohistochemistry(P), ELISA

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Karagianni F, et al. (2022) Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma. Cancers, 14(4).

Chen IT, et al. (2021) Promyelocytic leukemia protein targets MK2 to promote cytotoxicity. EMBO reports, 22(12), e52254.

Xian H, et al. (2021) Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity, 54(7), 1463.

Ortiz A, et al. (2019) An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer cell, 35(1), 33.